Switzerland / Ecuador / Netherlands / South Africa / Colombia / France / Japan / Uganda / Brazil / Australia / Tanzania / Korea / United Kingdom / China / India / Denmark / Germany / Central African Republic / Sweden / New Zealand / Sudan / Congo / Belgium / United States / Angola / Vietnam / Chad / Nigeria / Bolivia / South Korea / Spain / /
Event
FDA Phase / Business Partnership / Natural Disaster / /
Facility
University of Bonn / Novartis Institute of Tropical Diseases / University of Dundee / University of California San Francisco / Pace University / Northwick Park Institute / Institute of Medical Microbiology / São Carlos campus / PIPELINE Research HAT Screen Hit / Laboratory of Microbiology / Broad Institute / University Hospital of Bonn / University of Antwerp / Drug Candidate Optimisation (CDCO)/Monash University / Federal University of Ouro Preto / NIH library / University of Campinas / University of Auckland / University of São Paulo / Public Health Institute / Murdoch University / Vall d’Hebron Hospital / /
IndustryTerm
internet access / chemical space / compound mining effort / therapy for the disease / a Chagas disease therapy / compound mining efforts / drug product / large international pharmaceutical / health services / manufacturing process / access-supporting network / visual-based highthroughput screening technology / chemical entities / chemical classes / manufacturing / health systems / compound mining / pharmaceutical development / biotechnology / manufacturing practices / chemical compounds / manufacturing sites / pharmaceutical / electricity / biopharmaceutical / treatment of HIV / healthcare level / well-annotated chemical compound libraries / pharmaceutical partners / mining / treatment of chronic Chagas disease / /
University Hospital of Bonn / World Health Organization / Federal University of Ouro Preto / Laboratory of Microbiology / Parasitology / and Hygiene / Monash University / Drug Discovery Unit / University of São Paulo / Murdoch University / d’Hebron Hospital in Spain / Institut Pasteur Korea / London School of Hygiene & Tropical Medicine / Infectious Disease Department / University of California San Francisco / University of Bonn / HAT Platform / National Institute of Health / University of Antwerp / TB Alliance / Tropical and Public Health Institute / Broad Institute / Novartis Institute of Tropical Diseases / Northwick Park Institute for Medical Research / University of Campinas / Centre for Drug Candidate Optimisation / Institute of Medical Microbiology / Immunology / and Parasitology / French Ethics Committee / Pace University / University of Dundee / Vall d’Hebron Hospital in Spain / University of Auckland / /
Person
Bill Gates / Christopher Viehbacher / Margaret Chan / Optimisation / /
Position
candidate for further exploration / MP R&D MODEL / STRATEGY / representative / Latin America SSG&PM / moving forward to pre-clinical development / core R&D MODEL / STRATEGY / PAEDIATRIC HIV FILARIAL DISEASES R&D MODEL / STRATEGY / R&D MODEL / STRATEGY / /
Product
Ambisome / Develop tablet / ntd / amphotericin B / Nokia E55 Smartphone / SCYX-7158 / HAT / Both compounds / SCYX-2035811 / E1224 / two / /
ProgrammingLanguage
RC / /
ProvinceOrState
California / North Carolina / /
PublishedMedium
Microbiology / /
Region
West Africa / South Sudan / Central Africa / sub-Saharan Africa / East Africa / Latin America / /
Technology
diagnostic tests / High-throughput screening / Drug Discovery / drug metabolism / biotechnology / pharmacokinetics / visual-based highthroughput screening technology / Drug development / /
DNDi ’s objective is to deliver 11 to 13 new treatments by 2018 and to maintain a robust pipeline to support long-term objectives. R&D MODEL, STRATEGY & PORTFOLIO IMPROVING CURRENT